Utility of the SERPINC1 Gene Test in Ischemic Stroke Patients With Antithrombin Deficiency

ObjectiveAntithrombin (AT) plays a critical role in the coagulation system, and its deficiency induces hypercoagulability. AT deficiency is caused not only by inherited variants in the SERPINC1 gene but also by acquired conditions. Therefore, AT deficiency alone could not ensure the presence of the...

Full description

Bibliographic Details
Main Authors: Seondeuk Kim, Woo-Jin Lee, Jangsup Moon, Keun-Hwa Jung
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Neurology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2022.841934/full
_version_ 1818539895318118400
author Seondeuk Kim
Woo-Jin Lee
Jangsup Moon
Jangsup Moon
Keun-Hwa Jung
Keun-Hwa Jung
author_facet Seondeuk Kim
Woo-Jin Lee
Jangsup Moon
Jangsup Moon
Keun-Hwa Jung
Keun-Hwa Jung
author_sort Seondeuk Kim
collection DOAJ
description ObjectiveAntithrombin (AT) plays a critical role in the coagulation system, and its deficiency induces hypercoagulability. AT deficiency is caused not only by inherited variants in the SERPINC1 gene but also by acquired conditions. Therefore, AT deficiency alone could not ensure the presence of the SERPINC1 mutation. We evaluated the utility of the SERPINC1 gene test in ischemic stroke, an important clinical type of arterial thrombosis.MethodsThis retrospective, observational study investigated symptomatic patients who underwent the SERPINC1 gene test because of decreased AT activity (<80%) during 2009-2021 at a tertiary hospital. For the detection of sequence variants in the SERPINC1 gene, direct Sanger sequencing and multiplex ligation-dependent probe amplification were performed. The phenotypes of patients with SERPINC1 gene mutations were examined, and the conditions associated with the pathogenic variants were analyzed.ResultsIn our cohort (n = 19), 13 of 19 patients (68.4%) had the pathogenic variant of the SERPINC1 gene. Ischemic stroke (n = 7) was significantly associated with the pathogenic variants (p = 0.044), and the pathogenicity detection rate was 100%. For any kind of arterial thrombosis (n = 8), the detection rate of the pathogenic variant was 87.5%, but was not statistically significant (p = 0.177). The detection rates of the pathogenic variant in ischemic stroke or arterial thrombosis groups were both higher than those in the venous thrombosis-only group (54.5%).ConclusionThe SERPINC1 gene test was useful in determining the cause of AT deficiency-related arterial thrombosis, especially ischemic stroke. We propose the diagnostic flow of SERPINC1-related ischemic stroke.
first_indexed 2024-12-11T21:48:10Z
format Article
id doaj.art-bcfccbdb589c4fd683febee3b26d8de1
institution Directory Open Access Journal
issn 1664-2295
language English
last_indexed 2024-12-11T21:48:10Z
publishDate 2022-06-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Neurology
spelling doaj.art-bcfccbdb589c4fd683febee3b26d8de12022-12-22T00:49:33ZengFrontiers Media S.A.Frontiers in Neurology1664-22952022-06-011310.3389/fneur.2022.841934841934Utility of the SERPINC1 Gene Test in Ischemic Stroke Patients With Antithrombin DeficiencySeondeuk Kim0Woo-Jin Lee1Jangsup Moon2Jangsup Moon3Keun-Hwa Jung4Keun-Hwa Jung5Department of Neurology, Seoul National University Hospital, Seoul, South KoreaDepartment of Neurology, Seoul National University Hospital, Seoul, South KoreaDepartment of Neurology, Seoul National University Hospital, Seoul, South KoreaDepartment of Genomic Medicine, Seoul National University Hospital, Seoul, South KoreaDepartment of Neurology, Seoul National University Hospital, Seoul, South KoreaProgram in Neuroscience, Seoul National University College of Medicine, Seoul, South KoreaObjectiveAntithrombin (AT) plays a critical role in the coagulation system, and its deficiency induces hypercoagulability. AT deficiency is caused not only by inherited variants in the SERPINC1 gene but also by acquired conditions. Therefore, AT deficiency alone could not ensure the presence of the SERPINC1 mutation. We evaluated the utility of the SERPINC1 gene test in ischemic stroke, an important clinical type of arterial thrombosis.MethodsThis retrospective, observational study investigated symptomatic patients who underwent the SERPINC1 gene test because of decreased AT activity (<80%) during 2009-2021 at a tertiary hospital. For the detection of sequence variants in the SERPINC1 gene, direct Sanger sequencing and multiplex ligation-dependent probe amplification were performed. The phenotypes of patients with SERPINC1 gene mutations were examined, and the conditions associated with the pathogenic variants were analyzed.ResultsIn our cohort (n = 19), 13 of 19 patients (68.4%) had the pathogenic variant of the SERPINC1 gene. Ischemic stroke (n = 7) was significantly associated with the pathogenic variants (p = 0.044), and the pathogenicity detection rate was 100%. For any kind of arterial thrombosis (n = 8), the detection rate of the pathogenic variant was 87.5%, but was not statistically significant (p = 0.177). The detection rates of the pathogenic variant in ischemic stroke or arterial thrombosis groups were both higher than those in the venous thrombosis-only group (54.5%).ConclusionThe SERPINC1 gene test was useful in determining the cause of AT deficiency-related arterial thrombosis, especially ischemic stroke. We propose the diagnostic flow of SERPINC1-related ischemic stroke.https://www.frontiersin.org/articles/10.3389/fneur.2022.841934/fullgenetic strokesSERPINC1 mutationischemic strokepathogenic variantantithrombin (AT) deficiency
spellingShingle Seondeuk Kim
Woo-Jin Lee
Jangsup Moon
Jangsup Moon
Keun-Hwa Jung
Keun-Hwa Jung
Utility of the SERPINC1 Gene Test in Ischemic Stroke Patients With Antithrombin Deficiency
Frontiers in Neurology
genetic strokes
SERPINC1 mutation
ischemic stroke
pathogenic variant
antithrombin (AT) deficiency
title Utility of the SERPINC1 Gene Test in Ischemic Stroke Patients With Antithrombin Deficiency
title_full Utility of the SERPINC1 Gene Test in Ischemic Stroke Patients With Antithrombin Deficiency
title_fullStr Utility of the SERPINC1 Gene Test in Ischemic Stroke Patients With Antithrombin Deficiency
title_full_unstemmed Utility of the SERPINC1 Gene Test in Ischemic Stroke Patients With Antithrombin Deficiency
title_short Utility of the SERPINC1 Gene Test in Ischemic Stroke Patients With Antithrombin Deficiency
title_sort utility of the serpinc1 gene test in ischemic stroke patients with antithrombin deficiency
topic genetic strokes
SERPINC1 mutation
ischemic stroke
pathogenic variant
antithrombin (AT) deficiency
url https://www.frontiersin.org/articles/10.3389/fneur.2022.841934/full
work_keys_str_mv AT seondeukkim utilityoftheserpinc1genetestinischemicstrokepatientswithantithrombindeficiency
AT woojinlee utilityoftheserpinc1genetestinischemicstrokepatientswithantithrombindeficiency
AT jangsupmoon utilityoftheserpinc1genetestinischemicstrokepatientswithantithrombindeficiency
AT jangsupmoon utilityoftheserpinc1genetestinischemicstrokepatientswithantithrombindeficiency
AT keunhwajung utilityoftheserpinc1genetestinischemicstrokepatientswithantithrombindeficiency
AT keunhwajung utilityoftheserpinc1genetestinischemicstrokepatientswithantithrombindeficiency